Abstract
Background
Diabetes mellitus (DM) is a risk factor for cardiovascular disease. However, its effect on procedural and follow-up performance after transcatheter aortic valve replacement (TAVR) remains controversial.
Methods and results
We performed an observational study of all consecutive patients treated with a transfemoral TAVR in a single-center cohort (n = 1818). All patients were stratified by diabetes status and gender. All-cause 3-year mortality was the primary endpoint. Male patients with DM were identified to have substantially increased 3-year mortality [125/314 (39.8%)] compared to males without DM [142/478 (29.7%), p < 0.01]. Male patients with DM had significantly higher 3-year mortality in comparison to female patients with (p < 0.01) or without DM (p < 0.01). There was no difference in 3-year mortality for female patients with [135/465 (29.0%)] and without DM [151/554 (27.3%); p = 0.70]. This increase in mortality in male DM patients was triggered by both cardiovascular and non-cardiovascular mortality. Furthermore, DM served as an independent predictor of 3-year mortality after TAVR selectively only in men. The interaction between male gender and diabetes mellitus was identified as an independent predictor of 3-year mortality [HR 1.88 (1.25; 2.82); p < 0.01]. DM did not affect 30-day mortality for the overall cohort and for males.
Conclusion
Males with DM are a high-risk subgroup of patients after TAVR and require close medical attention including aggressive therapy of modifiable risk factors. Intensified diabetes management may improve long-term survival after TAVR.
Similar content being viewed by others
Abbreviations
- DM:
-
Diabetes mellitus
- TAVR:
-
Transcatheter aortic valve replacement
- BMI:
-
Body mass index
- CAD:
-
Coronary artery disease
- NYHA:
-
New York Heart Association
- STS:
-
Society of Thoracic Surgeons
- PAD:
-
Peripheral artery disease
- MI:
-
Myocardial infarction
- CABD:
-
Coronary artery bypass grafting
- PCI:
-
Percutaneous coronary intervention
- CKD:
-
Chronic kidney disease
- VARC:
-
Valve Academic Research Consortium
- AR:
-
Aortic valve regurgitation
- MR:
-
Mitral valve regurgitation
- PPM:
-
Permanent pacemaker
- ICD:
-
Implantable cardioverter/defibrillator
References
Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375(9733):2215–2222. https://doi.org/10.1016/s0140-6736(10)60484-9
Katz R, Wong ND, Kronmal R, Takasu J, Shavelle DM, Probstfield JL, Bertoni AG, Budoff MJ, O’Brien KD (2006) Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 113(17):2113–2119. https://doi.org/10.1161/CIRCULATIONAHA.105.598086
Owens DS, Katz R, Takasu J, Kronmal R, Budoff MJ, O’Brien KD (2010) Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA). Am J Cardiol 105(5):701–708. https://doi.org/10.1016/j.amjcard.2009.10.071
Otto CM, Prendergast B (2014) Aortic-valve stenosis–from patients at risk to severe valve obstruction. N Engl J Med 371(8):744–756. https://doi.org/10.1056/NEJMra1313875
Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF (2010) Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 8:29. https://doi.org/10.1186/1478-7954-8-29
Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (2014) Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol 2 (8):634–647. https://doi.org/10.1016/s2213-8587(14)70102-0
Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW, Kappetein AP (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376(14):1321–1331. https://doi.org/10.1056/NEJMoa1700456
Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374(17):1609–1620. https://doi.org/10.1056/NEJMoa1514616
Holmes DR Jr, Nishimura RA, Grover FL, Brindis RG, Carroll JD, Edwards FH, Peterson ED, Rumsfeld JS, Shahian DM, Thourani VH, Tuzcu EM, Vemulapalli S, Hewitt K, Michaels J, Fitzgerald S, Mack MJ (2015) Annual outcomes with transcatheter valve therapy: from the STS/ACC TVT registry. J Am Coll Cardiol 66(25):2813–2823. https://doi.org/10.1016/j.jacc.2015.10.021
Gerckens U, Tamburino C, Bleiziffer S, Bosmans J, Wenaweser P, Brecker S, Guo J, Linke A (2017) Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study. Eur Heart J. https://doi.org/10.1093/eurheartj/ehx295
Ando T, Takagi H, Briasoulis A, Umemoto T (2017) Does diabetes mellitus impact prognosis after transcatheter aortic valve implantation? Insights from a meta-analysis. J Cardiol. https://doi.org/10.1016/j.jjcc.2017.01.005
Mina GS, Gill P, Soliman D, Reddy P, Dominic P (2017) Diabetes mellitus is associated with increased acute kidney injury and 1-year mortality after transcatheter aortic valve replacement: a meta-analysis. Clin Cardiol 40(9):726–731. https://doi.org/10.1002/clc.22723
Sun Y, Liu X, He Y, Tang M, Zhu Q, Xu X, Guo D, Shi K, Hu P, Wang L, Kong H, Jiang J, Lin X, Xu Q, Gao F, Wang J (2017) Meta-analysis of impact of diabetes mellitus on outcomes after transcatheter aortic valve implantation. Am J Cardiol 119(4):623–629. https://doi.org/10.1016/j.amjcard.2016.10.048
Saad M, Nairooz R, Pothineni NVK, Almomani A, Kovelamudi S, Sardar P, Katz M, Abdel-Wahab M, Bangalore S, Kleiman NS, Block PC, Abbott JD (2017) Long-term outcomes with transcatheter aortic valve replacement in women compared with men: evidence from a meta-analysis. JACC Cardiovasc Interv. https://doi.org/10.1016/j.jcin.2017.08.015
Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodes-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 60(15):1438–1454. https://doi.org/10.1016/j.jacc.2012.09.001
Sherif MA, Zahn R, Gerckens U, Sievert H, Eggebrecht H, Hambrecht R, Sack S, Richardt G, Schneider S, Senges J, Brachmann J (2014) Effect of gender differences on 1-year mortality after transcatheter aortic valve implantation for severe aortic stenosis: results from a multicenter real-world registry. Clin Res Cardiol 103(8):613–620. https://doi.org/10.1007/s00392-014-0690-6
Holmes DR Jr, Brennan J, Rumsfeld JS et al (2015) Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA 313(10):1019–1028. https://doi.org/10.1001/jama.2015.1474
Farhan S, Baber U, Vogel B, Aquino M, Chandrasekhar J, Faggioni M, Giustino G, Kautzky-Willer A, Sweeny J, Shah S, Vijay P, Barman N, Moreno P, Kovacic J, Dangas G, Kini A, Mehran R, Sharma S (2017) Impact of diabetes mellitus on ischemic events in men and women after percutaneous coronary intervention. Am J Cardiol 119(8):1166–1172. https://doi.org/10.1016/j.amjcard.2016.12.035
Rodes-Cabau J, Webb JG, Cheung A, Ye J, Dumont E, Osten M, Feindel CM, Natarajan MK, Velianou JL, Martucci G, DeVarennes B, Chisholm R, Peterson M, Thompson CR, Wood D, Toggweiler S, Gurvitch R, Lichtenstein SV, Doyle D, DeLarochelliere R, Teoh K, Chu V, Bainey K, Lachapelle K, Cheema A, Latter D, Dumesnil JG, Pibarot P, Horlick E (2012) Long-term outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience. J Am Coll Cardiol 60(19):1864–1875. https://doi.org/10.1016/j.jacc.2012.08.960
Bleiziffer S, Bosmans J, Brecker S, Gerckens U, Wenaweser P, Tamburino C, Linke A (2017) Insights on mid-term TAVR performance: 3-year clinical and echocardiographic results from the CoreValve ADVANCE study. Clin Res Cardiol 106(10):784–795. https://doi.org/10.1007/s00392-017-1120-3
Barbanti M, Latib A, Sgroi C, Fiorina C, De Carlo M, Bedogni F, De Marco F, Ettori F, Petronio AS, Colombo A, Testa L, Klugmann S, Poli A, Maffeo D, Maisano F, Aruta P, Gulino S, Giarratana A, Patane M, Cannata S, Imme S, Mangoni L, Rossi A, Tamburino C (2014) Acute kidney injury after transcatheter aortic valve implantation with self-expanding CoreValve prosthesis: results from a large multicentre Italian research project. EuroIntervention 10(1):133–140. https://doi.org/10.4244/eijv10i1a20
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Axel Linke: reports grants and personal fees from Medtronic, personal fees from St. Jude Medical, grants from Claret Medical, personal fees and other from Claret Medical, personal fees from Boston Scientific, personal fees from Bard, personal fees from Edwards, outside the submitted work. Florian Schlotter: No conflict of Interest. Stephan Haussig: No conflict of Interest. Felix J. Woitek: No conflict of Interest. Georg Stachel: No conflict of Interest. Jennifer Adam: No conflict of Interest. Robert Höllriegel: No conflict of Interest. Anna Lindner: No conflict of Interest. Friedrich W. Mohr: No conflict of Interest. Gerhard Schuler: No conflict of Interest. Philipp Kiefer: No conflict of Interest. Sergey Leontyev reports other from St. Jude Medical, other from Medtronic, outside the submitted work. Holger Thiele: No conflict of interest. Michael M. Borger: Speakers’ honoraria and consulting fees from Edwards Lifesciences, Medtronic, and CryoLife, outside the submitted work. David Holzhey reports other from Symetis, other from Medtronic, outside the submitted work. Norman Mangner: No conflict of Interest.
Additional information
Axel Linke and Florian Schlotter contributed equally to this work and should be regarded as shared first authors.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplemental Figure 1
: Kaplan-Meier analyses for: a) 30-day survival; b) one-year survival; c) landmark analysis 30 days to one year after TAVR; d) three-year cardiovascular mortality; e) three-year non-cardiovascular mortality; four group comparison between non-diabetic females, diabetic females, non-diabetic males and diabetic males (PPTX 277 KB)
Rights and permissions
About this article
Cite this article
Linke, A., Schlotter, F., Haussig, S. et al. Gender-dependent association of diabetes mellitus with mortality in patients undergoing transcatheter aortic valve replacement. Clin Res Cardiol 108, 39–47 (2019). https://doi.org/10.1007/s00392-018-1309-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-018-1309-0